July 27, 2020

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Category: Article Summary

Topic: Testing and Treatment

• A randomized trial of hydroxychloroquine, alone or with azithromycin, for treatment of mild- to moderate COVID-19 found no effect on improving clinical status at 15 days after hospital admission. Cavalcanti et al. conducted a multicenter, randomized, open-label, three-arm controlled trial (n=504) in Brazil and found that the odds of having a higher score (worse clinical status) on a 7-point ordinal scale at 15 days was not affected by hydroxychloroquine alone (OR=1.21, 95% CI 0.69-2.11), or hydroxychloroquine and azithromycin (OR=0.99, 95% CI 0.57-1.73), compared to standard care. 

Cavalcanti et al. (July 23, 2020). Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2019014